Welcome to our dedicated page for nyse news (Ticker: nyse), a resource for investors and traders seeking the latest updates and insights on nyse stock.
Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) is a pioneering biopharmaceutical company focused on developing targeted radiotherapies for treating cancer. Founded with the mission of improving survival outcomes for patients with difficult-to-treat cancers, Actinium leverages its proprietary Antibody Radiation Conjugates (ARCs) to deliver potent radiation directly to cancer cells while sparing healthy tissue.
Actinium's leading candidates include Iomab-B and Actimab-A. Iomab-B is a radioimmunotherapy intended for conditioning before bone marrow transplants in patients with active relapsed or refractory acute myeloid leukemia (r/r AML). The pivotal Phase 3 SIERRA trial has demonstrated Iomab-B's ability to significantly improve overall survival and remission rates, particularly in patients with the high-risk TP53 mutation. Advanced filings for Biologics License Application (BLA) and Marketing Authorization Application (MAA) are underway.
Actimab-A, targeting CD33, is being developed as a therapeutic for r/r AML and is currently progressing under the National Cancer Institute’s CRADA pivotal development path. This candidate, along with Iomab-B, has shown promising results in overcoming genetic mutations and providing high response rates.
In addition to its robust pipeline, Actinium is actively involved in partnerships to extend its technology platform to solid tumors. Notable collaborations include those with Astellas Pharma, AVEO Oncology, and LG Chem Life Sciences. The company holds an extensive intellectual property portfolio with over 230 patents and patent applications.
Recent developments include the initiation of a clinical trial for Iomab-ACT, a next-generation conditioning agent for cell and gene therapies such as CAR T-cell therapy. This trial, led by the University of Texas Southwestern Medical Center, aims to replace traditional chemotherapy conditioning with targeted radiotherapy to reduce toxicities and improve patient outcomes.
Actinium’s strong presence at major scientific conferences such as the American Society of Hematology (ASH), European Bone Marrow Transplant Society (EBMT), and Tandem Meetings of ASTCT and CIBMTR underscores its commitment to advancing targeted radiotherapies and highlights the potential of its innovative treatments in transforming cancer care.
Actinium Pharmaceuticals, Inc. (NYSE: ATNM) announced positive results from its pivotal Phase 3 SIERRA trial of Iomab-B for treating elderly patients with active relapsed or refractory acute myeloid leukemia (AML). The trial met its primary endpoint, achieving a durable complete remission (dCR) of 6 months post-treatment, with a p-value of <0.0001. Iomab-B demonstrated significant potential to increase patient access to bone marrow transplants (BMT) and improve patient outcomes, prompting the company to advance its Biologics License Application (BLA) submission to the FDA.
Actinium Pharmaceuticals, Inc. (NYSE: ATNM) announced a senior-level expansion of its clinical organization, strengthening its expertise in bone marrow transplant and acute myeloid leukemia. Key hires include Madhuri Vusirikala, MD, Akash Nahar, MD, Patrik Brodin, Ph.D., and Elaina Haeuber, enhancing the company's operational capabilities for pivotal programs Iomab-B and Actimab-A. Topline data from the Phase 3 SIERRA trial for Iomab-B is expected in Q4 2022. This expansion aims to advance clinical development and improve patient outcomes in hematological malignancies.
Actinium Pharmaceuticals, Inc. (NYSE: ATNM) will participate in the virtual Bio-Europe conference from November 2-4, 2022. The event is the largest biopharma partnering meeting in Europe, featuring over 4,000 attendees and 27,000 scheduled 1-on-1 meetings. Actinium's business development team will conduct individual meetings, which can be requested through the partneringONE® system. The company focuses on targeted radiotherapies for cancer treatment, with key products including I-131 apamistamab (Iomab-B) and Actimab-A, both undergoing clinical trials.
Actinium Pharmaceuticals (NYSE: ATNM) provided a corporate update on September 21, 2022, highlighting key upcoming milestones in its clinical pipeline. Key data releases expected include topline results from the pivotal Phase 3 SIERRA trial for Iomab-B and overall survival data from the Actimab-A CLAG-M combination trial, both anticipated in Q4 2022. The company reported approximately $116 million in cash and equivalents as of Q2 2022, sufficient to support operations through mid-2025, facilitating its commitment to advancing targeted radiotherapies for patients with high unmet medical needs.
Volta Inc. (NYSE: VLTA) is set to release its first quarter 2022 results on Friday, May 13, 2022, before market open. This announcement will be followed by a conference call at 8:00 a.m. Eastern Time. Investors can listen to the call through the Investor Relations section of Volta's website or via telephone. A replay of the call will be available approximately three hours after it concludes, lasting until May 27, 2022. Volta is a leading provider of commerce-centric EV charging networks, aiming to support the transition to electric mobility.
Horace Mann Educators Corporation (NYSE:HMN) will release its fourth-quarter and full-year 2021 results on February 1, after market close. A conference call to discuss these results is scheduled for February 2 at 10 a.m. ET. The financial information will be available on the company’s investor website. Founded in 1945, Horace Mann is dedicated to providing financial services tailored for educators, emphasizing its mission to help them achieve lifelong financial success.
Rockley Photonics (NYSE: RKLY) has signed partnership agreements with five top global consumer electronics manufacturers to enhance its non-invasive VitalSpex™ biomarker sensing platform. These collaborations will enable the integration of advanced biomarker measurements into consumer devices like smartwatches and wristbands, expanding Rockley's market presence. The platform aims to deliver real-time health insights by measuring various biomarkers including body temperature, blood pressure, and glucose trends. Rockley is conducting human studies to refine its sensing technology.
CCC Intelligent Solutions has successfully refinanced its secured credit facility, establishing an $800 million senior secured term loan and a $250 million senior secured revolving credit facility. This strategic move aims to bolster the company's balance sheet, with a reported 50% reduction in net leverage and $20 million in decreased projected annual cash interest payments. The term loan has a maturity date of September 21, 2028, while the revolving facility matures on September 21, 2026. The refinancing aims to support growth initiatives and enhance value for customers and shareholders.
Stem, Inc. (NYSE: STEM) has entered a memorandum of understanding with CleanCapital for a new financing partnership aimed at enhancing clean energy storage solutions. This collaboration will establish Stem as CleanCapital's preferred energy storage provider, focusing on mid-market commercial energy storage and small utility projects up to 30 MW across the U.S. CleanCapital, backed by a $300 million investment from Manulife Investment Management, aims to expand its clean energy portfolio. The partnership is expected to drive significant investments in energy storage and solar projects.
FAQ
What is Actinium Pharmaceuticals' primary focus?
What is Iomab-B?
What recent achievements has Actinium Pharmaceuticals made?
Who are Actinium Pharmaceuticals' key partners?
What is Actimab-A?
What are the key results from the SIERRA trial?
What is the significance of Actinium's technology platform?
How many patents does Actinium Pharmaceuticals hold?
What is the purpose of Iomab-ACT?
Where can I find more information about Actinium Pharmaceuticals?
